American Association for Cancer Research
15417786mcr140300-sup-132169_2_supp_2700687_ndfdld.png (26.78 kB)

Supplementary Figure S1 from miR-629 Targets TRIM33 to Promote TGFβ/Smad Signaling and Metastatic Phenotypes in ccRCC

Download (26.78 kB)
posted on 2023-04-03, 17:49 authored by Kentaro Jingushi, Yuko Ueda, Kaori Kitae, Hiroaki Hase, Hiroshi Egawa, Ikumi Ohshio, Ryoji Kawakami, Yuri Kashiwagi, Yohei Tsukada, Takumi Kobayashi, Wataru Nakata, Kazutoshi Fujita, Motohide Uemura, Norio Nonomura, Kazutake Tsujikawa

Supplementary Figure S1. A, ACHN cells were transfected with miR-629 mimic or negative control mimic for 72 h. TRIM33 mRNA levels were examined by quantitative real-time PCR. Data are the relative expression normalized to GAPDH mRNA. Values are means {plus minus} S.D. of 3 independent experiments. **p < 0.01 vs. control mimic. B, The expression of miR-629 and TRIM33 mRNAs expression (fold-change: tumor vs. normal) were examined in 41 matched-pair samples of ccRCC by quantitative real-time PCR, and the relationship was evaluated.



Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney, and clear cell RCC (ccRCC) represents its most common histological subtype. To identify a therapeutic target for ccRCC, miRNA expression signatures from ccRCC clinical specimens were analyzed. miRNA microarray and real-time PCR analyses revealed that miR-629 expression was significantly upregulated in human ccRCC compared with adjacent noncancerous renal tissue. Functional inhibition of miR-629 by a hairpin miRNA inhibitor suppressed ccRCC cell motility and invasion. Mechanistically, miR-629 directly targeted tripartite motif-containing 33 (TRIM33), which inhibits the TGFβ/Smad signaling pathway. In clinical ccRCC specimens, downregulation of TRIM33 was observed with the association of both pathologic stages and grades. The miR-629 inhibitor significantly suppressed TGFβ-induced Smad activation by upregulating TRIM33 expression and subsequently inhibited the association of Smad2/3 and Smad4. Moreover, a miR-629 mimic enhanced the effect of TGFβ on the expression of epithelial–mesenchymal transition–related factors as well as on the motility and invasion in ccRCC cells. These findings identify miR-629 as a potent regulator of the TGFβ/Smad signaling pathway via TRIM33 in ccRCC.Implications: This study suggests that miR-629 has biomarker potential through its ability to regulate TGFβ/Smad signaling and accelerate ccRCC cell motility and invasion. Mol Cancer Res; 13(3); 565–74. ©2014 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager